12 November 2015 - Gilead Sciences, Inc. today announced that the U.S. FDA has approved Harvoni (ledipasvir with sofosbuvir) for expanded use in patients with genotype 4, 5 and 6 chronic hepatitis C virus infection and in patients co-infected with HIV.

For more details, go to: http://www.gilead.com/news/press-releases/2015/11/us-fda-approves-new-indications-for-harvoni-gileads-oncedaily-single-tablet-regimen-for-chronic-hepatitis-c